XML 25 R15.htm IDEA: XBRL DOCUMENT
v3.21.2

Share-Based Compensation Plans | 6 Months Ended
--- | ---
Jun. 30, 2021
Share-Based Compensation Plans |
Share-Based Compensation Plans | 11. Share-Based Compensation Plans During the three and six months ended June 30, 2021, the Company recognized $327,000 and $872,000, respectively, of compensation expense associated with stock option and restricted stock awards granted in years 2015 through 2020. During the three and six months ended June 30, 2020, the Company recognized $350,000 and $701,000, respectively, of compensation expense associated with stock option and restricted stock awards granted in years 2016 through 2019. During the first quarter of 2021, the Company’s Board of Directors approved extending the expiration date of stock options granted in years 2015 and 2016. The original expiration date of the stock options granted in 2015 was August 25, 2021, and was extended by two years to August 25, 2023. The original expiration date of the stock options granted in 2016 was August 25, 2022, and was extended by one year to August 25, 2023. The Company recorded an additional $232,000 of compensation expense in the first quarter due to the exercise periods of these options being extended. The following table summarizes the Company’s stock option activity for the six-month period ended June 30, 2021: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Weighted | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted | ​ | Average | ​ | ​ | ​
​ | ​ | ​ | ​ | Average | ​ | Remaining | ​ | Aggregate
​ | ​ | ​ | ​ | Exercise | ​ | Contractual | ​ | Intrinsic
​ |  | Shares |  | Price |  | Term (Years) |  | Value*
Outstanding at December 31, 2020 |  | 1,125,383 | ​ | $ | 25.62 |  |  |  | ​ |
Granted |  | — | ​ | $ | — |  |  |  | ​ |
Exercised |  | — | ​ | $ | — |  |  |  | ​ |
Forfeited or expired |  | (19,780) | ​ | $ | 23.15 |  |  |  | ​ |
Outstanding at June 30, 2021 |  | 1,105,603 | ​ | $ | 25.67 |  | 4.9 | ​ | $ | 788,000
Exercisable at June 30, 2021 |  | 644,862 | ​ | $ | 26.74 |  | 2.6 | ​ | $ | 11,000
* The aggregate intrinsic value of outstanding and exercisable stock options is defined as the difference between the market value of the Company's stock on June 30, 2021 of $22.37 and the exercise price multiplied by the number of in-the-money outstanding and exercisable stock options. The following table summarizes the Company’s restricted stock award activity for the six-month period ended June 30, 2021: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Weighted | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted | ​ | Average | ​ | ​ | ​
​ | ​ | Shares of | ​ | Average | ​ | Remaining | ​ | Aggregate
​ | ​ | Restricted | ​ | Grant Date | ​ | Contractual | ​ | Intrinsic
​ |  | Stock |  | Fair Value |  | Term (Years) |  | Value*
Non-vested at December 31, 2020 |  | 72,490 | ​ | $ | 23.77 |  |  |  | ​ |
Issued |  | — | ​ | ​ | — |  |  |  | ​ |
Vested |  | (1,350) | ​ |  | 24.46 |  |  |  | ​ |
Forfeited |  | — | ​ |  | — |  |  |  | ​ |
Non-vested at June 30, 2021 |  | 71,140 | ​ | $ | 23.76 |  | 2.2 | ​ | $ | 1,591,000
* The aggregate intrinsic value of non-vested restricted stock was calculated using the market value of the Company’s stock on June 30, 2021 of $22.37 multiplied by the number of non-vested restricted shares outstanding.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration